Caladrius Biosciences, Inc. (CLBS): Price and Financial Metrics


Caladrius Biosciences, Inc. (CLBS): $6.40

-1.26 (-16.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLBS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLBS Stock Price Chart Interactive Chart >

Price chart for CLBS

CLBS Price/Volume Stats

Current price $6.40 52-week high $9.75
Prev. close $0.51 52-week low $0.38
Day low $5.73 Volume 1,796,440
Day high $9.75 Avg. volume 522,308
50-day MA $0.52 Dividend yield N/A
200-day MA $0.65 Market Cap 387.49M

Caladrius Biosciences, Inc. (CLBS) Company Bio


Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies.


CLBS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLBS Latest Social Stream


Loading social stream, please wait...

View Full CLBS Social Stream

Latest CLBS News From Around the Web

Below are the latest news stories about CALADRIUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CLBS as an investment opportunity.

Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing

NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3RSjiX2The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accep

Yahoo | September 16, 2022

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today annou

Yahoo | September 15, 2022

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

All Merger-related proposals approved at the Annual Meeting of StockholdersBASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganiz

Yahoo | September 14, 2022

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors, advisors, and analysts are invited to attend this virtual event showcasing live executive presentations from companies

Yahoo | September 12, 2022

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Location: Lotte New York Palace Hotel in New York C

Yahoo | September 8, 2022

Read More 'CLBS' Stories Here

CLBS Price Returns

1-mo N/A
3-mo -14.67%
6-mo -17.77%
1-year -54.50%
3-year -84.76%
5-year -87.56%
YTD -49.30%
2021 -41.15%
2020 -43.03%
2019 -29.49%
2018 1.42%
2017 24.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6494 seconds.